Miragen Therapeutics, Inc. (MGEN), a Healthcare Biotechnology business, saw its stock exchange 1.9700 shares, a pullback against to its 10-day trading volume of 7.59M.
Miragen Therapeutics, Inc. (MGEN) stock traded at $1.9700, up +0.2800 cents or +16.57% on the day.
Wall Street brokerages expect Miragen Therapeutics Inc (NASDAQ:MGEN) to report $970,000.00 in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Miragen Therapeutics’ earnings. The lowest sales estimate is $700,000.00 and the highest is $1.50 million. Miragen Therapeutics posted sales of $480,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 102.1%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.
Miragen Therapeutics, Inc. (MGEN) announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA, which is taking place from January 30th to February 1st. Of note are the data from the subtype of aggressive ATLL patients who at study entry had persistent residual disease after chemotherapy or other therapy.
Total Revenue for Miragen Therapeutics, Inc. (MGEN) is $4.06M, Gross Profit is $-22.04M and the EBITDA is $-40.97M.
Miragen Therapeutics, Inc. (MGEN) Technical Research:
The average 10-day trading volume of Miragen Therapeutics, Inc. (MGEN) is 7.59M compared to 1.34M over the last 3 months which indicates a pop in trading activity. At the time of writing this article, Miragen Therapeutics, Inc. (MGEN) has a 50-day moving average of $0.6806 and a 200-day moving average of $0.9687. These moving averages are popular technical details which investors use to analyze price trends of Miragen Therapeutics, Inc. (MGEN).
Approximately 1.93% of the shares of the company are short sold from investors betting the stock may trade lower. The beta value on Miragen Therapeutics, Inc. (MGEN) stock is 1.50, indicating its 49.61% to 24.69% more volatile than the overall market.
Technically, MGEN’s short term support levels are around $1.57, $1.41 and $1.17 on the downside.
Based on technical analysis, MGEN has short term rating of Bullish (0.32), Intermediate rating of Bullish (0.44) and the long-term rating of Bullish (0.43) giving it an overall rating of Bullish (0.40).
MGEN is trading 343.18% off its 52 week low at $0.44 and -48.68% off its 52 week high of $3.80. Performance wise, MGEN stock has recently shown investors 184.46% pop in a week, 232.61% pop in a month and 132.46% pop in the past quarter.
On the flip side, Miragen Therapeutics, Inc. (MGEN) has shown a return of 252.16% since the beginning of the year.
Miragen Therapeutics, Inc. (MGEN) Key Details:
Miragen Therapeutics, Inc. (MGEN) is a micro-cap company with a market cap value of $68.678M. MGEN insiders hold roughly 9.17% of the shares.
On Dec-31-18 B. Riley FBR Resumed MGEN as Buy at $18.50. On Jan-04-19 Robert W. Baird Initiated MGEN as Outperform and on Dec-12-19 Robert W. Baird Downgrade MGEN as Outperform → Neutral at $5 → $1.
There are currently 29.74M shares in the float and 32.22M shares outstanding. There are 1.93% shares short in MGENs float.
The industry rank for Miragen Therapeutics, Inc. (MGEN) is 73 out of 255 ranking it at the Top 29% .
Miragen Therapeutics, Inc. (MGEN) Key Fundamentals:
MGEN last 2 years revenues have decreased from $8,386 to $4,057 showing a downtrend.
Wall Street expects Miragen Therapeutics, Inc. (MGEN) to report an EPS next Qtr profit of -0.25 and a profit of 40.20% next year.
The growth rate on MGEN this year is -1.82 compared to an industry 8.60. However, MGENs next year’s growth rate is 28.57 compared to an industry 8.40.
The book value per share (mrq) is 0.75 and cash per share (mrq) is 1.05. Giving them a price/book (mrq) of 2.26 compared to an industry of 3.75 and MGENs price/cash flow (mrfy) is NA compared to an industry of 12.30.
MGEN fundamental ratios shows an EPS growth vs. previous year -1.12 and EPS growth vs. previous quarter -0.25.
About Miragen Therapeutics, Inc. (MGEN):
Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado.